Skip to main content
Fig. 2 | Journal of Biomedical Science

Fig. 2

From: Preclinical and clinical aspects of TNF-α and its receptors TNFR1 and TNFR2 in breast cancer

Fig. 2

Antitumorigenic effects of TNF-α in breast cancer. a TNF-α impairs cell cycle progression, preventing IGF-I-dependent DNA synthesis and arresting cells in G0/G1 phase in ER positive breast cancer cells (7). b Administration of tumor vasculature-targeted TNF-α synergizes chemotherapy in models of mammary adenocarcinoma (38). c TNF-α > 6.20 pg/ml is associated with 52% less risk of progression of breast cancer (54). d The use of tumor-homing peptides fused to TNF-α results in increased anti-tumor activity (47). e Nanoparticles-coupled TNF-α improve response to radiation, chemotherapy and cryosurgery, resulting in increased antitumor response (40–44)

Back to article page